The U.S. Food and Drug Administration (FDA) has rejected a request to authorize a drug as a COVID-19 treatment for hospitalized patients.
Florida-based Veru said March 2 that the FDA informed the company it would not grant emergency use authorization (EUA) for sabizabulin, the drug.
Veru asked in 2022 for authorization for the drug as a treatment for hospitalized adults with moderate to severe COVID-19 who were deemed high risk for Acute Respiratory Distress Syndrome, a lung condition that proves fatal in some cases.
“In communicating its decision, the FDA stated that despite the FDA declining to issue an EUA for sabizabulin at this time, the FDA remains committed to working with the Company for the development of sabizabulin,” Veru said in a statement….